Skip to main content
Premium Trial:

Request an Annual Quote

Cenix Expands AstraZeneca Agreement

NEW YORK (GenomeWeb News) – Cenix Bioscience said today that it has expanded an oncology drug research agreement with AstraZeneca to include RNAi-based studies for respiratory and inflammation-related conditions.

Under the new agreement, which expands upon a deal announced in March, Cenix will complete at least three projects using its RNAi gene silencing technology as well as image analysis using Definiens’ Cellenger platform.

These studies will involve multi-pass genome-scale screens using assays developed by AstraZeneca in high-throughput RNAi studies in 384-well and 1,536-well formats.

Financial terms of the expanded agreement were not released.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.